These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 26248256)

  • 1. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
    Cheah CY; Fowler NH; Neelapu SS
    Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting immune checkpoints in lymphoma.
    Ansell SM
    Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors in Hodgkin's lymphoma.
    Jezeršek Novaković B
    Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
    Lee J; Kefford R; Carlino M
    Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death-1 inhibition in lymphoma.
    Hawkes EA; Grigg A; Chong G
    Lancet Oncol; 2015 May; 16(5):e234-45. PubMed ID: 25943068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 inhibitors.
    Sunshine J; Taube JM
    Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
    Allen PB; Gordon LI
    Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
    Ansell SM
    J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-1 therapy in melanoma.
    Homet Moreno B; Parisi G; Robert L; Ribas A
    Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.